The Science Behind Depuff Please

Diosmetin is the aglycone of diosmin, the flavonoid that carries most of the clinical research in phlebology. The distinction matters pharmacologically. Oral diosmin is not absorbed intact: Cova and colleagues (1992) dosed healthy volunteers and, at the sensitivity of their HPLC and LC-MS assays, found no parent compound in plasma - only diosmetin, with a long plasma elimination half-life of 26 to 43 hours. Every clinical result attributed to oral diosmin is therefore, in substance, a result attributable to circulating diosmetin.

The clinical record is unusually deep for a plant flavonoid. Kakkos and Nicolaides (2018) pooled seven randomised, double-blind, placebo-controlled trials of micronised purified flavonoid fraction (roughly 90 percent diosmin plus 10 percent hesperidin and related flavonoids) covering 1,692 patients with chronic venous disease. Against placebo, MPFF significantly improved pain, leg heaviness, the sensation of swelling, cramps and paraesthesia, and reduced ankle circumference. The authors graded the overall body of evidence as high quality using GRADE.

For diosmin alone, Serra et al. (2021) randomised 72 adults with CEAP C2 to C4 chronic venous disease to 450 mg micronised diosmin once daily by mouth or placebo for eight weeks. Leg circumference fell 3.63 percent at week 4 (p = 0.033) and 4.67 percent at week 8 (p = 0.016) in the active arm, versus 0.07 percent and 0.32 percent on placebo. Pain on the visual analogue scale improved by week 8 (p = 0.014), and the Global Impression Scale rose from 58.48 to 84.43 versus 61.96 to 67.46 on placebo (p < 0.001).

On mechanism in skin tissue itself, Boisnic et al. (2023) applied diosmetin-3-O-beta-D-glucuronide, the main circulating metabolite, to ex vivo human skin. After a substance P inflammatory challenge it reduced interleukin-8 secretion by up to 49.6 percent and reduced the number of dilated capillaries; under UVB it lowered hydrogen peroxide production and DNA damage markers.

Hesperetin is the aglycone of hesperidin, the citrus flavonoid that accompanies diosmin in micronised purified flavonoid fraction. As with diosmin, the glycoside is too large to cross membranes intact; gut microbiota hydrolyse it, and the aglycone hesperetin, at 302.28 g/mol, is what circulates.

The most informative single trial is Rizza et al. (2011), a randomised, placebo-controlled, double-blind crossover study in 24 adults with metabolic syndrome. Oral hesperidin at 500 mg once daily for three weeks increased flow-mediated dilation of the brachial artery to 10.26 plus or minus 1.19 percent, versus 7.78 plus or minus 0.76 percent on placebo (p = 0.02), and lowered high-sensitivity C-reactive protein, serum amyloid A protein and soluble E-selectin. Flow-mediated dilation is an instrumented measure of conduit artery endothelial function, not a questionnaire. In parallel cell work the authors showed that hesperetin stimulated phosphorylation of endothelial nitric oxide synthase and increased nitric oxide output, a step that required generation of hydrogen peroxide. That is a coherent vascular mechanism, measured in humans, with a molecular explanation behind it.

Hesperidin is also a component of the most studied flavonoid preparation in phlebology. In the micronised purified flavonoid fraction studied by Kakkos and Nicolaides (2018) across seven randomised trials and 1,692 patients with chronic venous disease, hesperidin makes up roughly 10 percent of the preparation, which was tested as a combined fraction rather than as separate flavonoids. Those trials showed significant improvements in pain, heaviness, the sensation of swelling and ankle circumference against placebo.

Quercetin is the most studied dietary flavonoid, and it is the ingredient in this formula whose penetration into human skin has been measured most directly.

Vicentini et al. (2008) showed that quercetin formulated in a water-in-oil microemulsion penetrated into the stratum corneum and into the epidermis plus dermis at 3, 6, 9 and 12 hours in vitro, and protected against UVB-induced skin damage in vivo. Scalia et al. (2013) measured in vivo human skin penetration of quercetin delivered from permeation enhancers, lipid nanoparticles and colloidal silica. dal Belo et al. (2009) measured skin penetration of quercetin and epigallocatechin-3-gallate from conventional cosmetic formulations. Across that literature the finding is consistent: quercetin reaches the living layers of human skin, and the vehicle sets the rate.

At 302.23 g/mol, quercetin sits comfortably under the 500 Dalton ceiling that Bos and Meinardi identified as the first filter for skin penetration - which is why it is a candidate for a skin-applied format at all.

Its systemic pharmacology is anti-inflammatory and has been quantified. Mohammadi-Sartang et al. (2017) meta-analysed seven randomised controlled trials contributing ten treatment arms and found that oral quercetin supplementation reduced circulating C-reactive protein by a weighted mean difference of -0.33 mg/L (95 percent CI -0.50 to -0.15; p < 0.001), with the effect concentrated in trials using at least 500 mg per day and in participants whose baseline CRP was below 3 mg/L. Tabrizi et al. (2020), across sixteen randomised trials in patients with metabolic syndrome and related disorders, reported a standardised mean difference for CRP of -0.64 (95 percent CI -1.03 to -0.25; p = 0.001).

The mechanistic bridge to a fluid-balance formula is microvascular: low-grade inflammation raises microvascular permeability, and permeability is one of the routes by which fluid moves from plasma into the interstitium.

L-carnitine's established biology is metabolic: it shuttles long-chain fatty acids across the inner mitochondrial membrane so they can be beta-oxidised. In vascular medicine that role has been tested in ischaemic muscle, where oxidative metabolism is compromised, and the trial record there is substantial.

The strongest evidence base is the 2021 Cochrane review by Kamoen and colleagues, covering twelve randomised controlled trials and 1,423 participants with intermittent claudication. Compared with placebo, propionyl-L-carnitine improved maximum walking distance by 50.86 metres (a 26 percent relative improvement) and pain-free walking distance by 32.98 metres (a 31 percent relative improvement), with a mean 0.09 improvement in the ankle-brachial index and better quality-of-life scores. The reviewers rated the overall certainty of evidence as moderate. Safety profiles were comparable to placebo.

The largest individual trial, Hiatt et al. (2001), randomised 155 patients with claudication to 2 g per day of oral propionyl-L-carnitine or placebo for six months. Peak walking time rose by 162 plus or minus 222 seconds (54 percent) on active treatment versus 75 plus or minus 191 seconds (25 percent) on placebo (p < 0.001), with parallel improvements in walking distance, walking speed and validated physical-functioning questionnaires.

Those trials were conducted in intermittent claudication, a disease of arterial inflow driven by atherosclerotic stenosis and muscle ischaemia. What they establish is that supplying carnitine to tissue with a high oxidative workload changes measurable tissue performance in humans - which is the mechanistic reason carnitine sits in this formula alongside the flavonoids.

Grape seed extract has the most directly relevant human endpoint of any ingredient in this formula, because one trial measured leg swelling itself rather than a surrogate.

Sano, Tokutake and Seo (2013) ran a double-blind, placebo-controlled crossover study in healthy Japanese women who then sat still for six hours - a deliberate model of the sedentary-work and long-haul-travel swelling that most people actually experience. Oral proanthocyanidin-rich grape seed extract significantly suppressed leg volume distension, the rise in body extracellular fluid, and leg water content compared with placebo. This is a healthy population and a normal-physiology endpoint, which makes it more transferable to a consumer product than the venous-disease literature is.

The VICTORY trial (Bae et al., 2026) supplies the clinical end. One hundred and seventy-six adults aged 19 to 80 with duplex-confirmed lower-extremity venous reflux were randomised to 150 mg Vitis vinifera seed extract twice daily by mouth plus lifestyle modification, or lifestyle modification alone, for twelve weeks. The supplemented group achieved significantly greater reductions in mean venous reflux time across superficial and deep veins, a higher proportion reaching improved reflux targets, and superior improvements in the Venous Clinical Severity Score and quality-of-life measures.

The proposed mechanism is capillary stabilisation: proanthocyanidins reduce vascular permeability and support endothelial and connective-tissue integrity, including inhibition of collagen- and elastin-degrading enzymes. That mechanism is documented in IN VITRO AND ANIMAL work rather than by direct human microvascular measurement.

Grape seed OPC is a mixed oligomeric extract - a distribution of monomeric, dimeric and higher oligomeric flavan-3-ols - rather than a single compound, and no single molecular weight describes it.

Nettle (Urtica dioica) is one of the longest-used plants in European herbal practice, and its pharmacology has been characterised in both animal and human work.

ANIMAL STUDY. Tahri et al. (2000) gave continuous intravenous perfusion of an aqueous Urtica dioica extract to rats and observed a dose-proportional fall in blood pressure of 15 to 38 percent alongside increased diuresis and natriuresis - increased urine output and increased sodium excretion. The route was intravenous and the species was the rat.

The best human trial of nettle is Safarinejad (2005), a six-month double-blind, placebo-controlled, randomised partial-crossover trial in 620 men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. By intention-to-treat analysis, 232 of 287 patients (81 percent) on nettle reported improved symptoms versus 43 of 271 (16 percent) on placebo (p < 0.001), and the International Prostate Symptom Score fell from 19.8 to 11.8 on nettle versus 19.2 to 17.7 on placebo (p = 0.002). That is a well-conducted, adequately powered trial in 620 men; its endpoint is the urinary symptom score, by the oral route.

Nettle is a multi-component botanical rather than a single molecule, so no single molecular weight describes it.